Support Your Liver Today with 15% OFF + Free Shipping

Signs of SIBO in Women: Symptoms, Causes and How It Damages Liver Function Over Time

by João Felgueira

You eat a healthy salad and spend the rest of the afternoon looking six months pregnant. You've tried eliminating gluten, then dairy, then everything enjoyable — and your gut still acts like it's waging a personal vendetta against you. You're tired in a way that sleep doesn't fix, your brain feels like it's operating through fog, and your doctor keeps telling you your blood tests are "basically normal."

If this sounds familiar, there's a condition you may not have heard of, or may have heard of in passing without fully understanding, that deserves serious attention: small intestinal bacterial overgrowth (SIBO). And what's even less well-known is that over time, untreated SIBO doesn't just wreck your digestion. It can quietly damage your liver.

What Is SIBO?

Your gut is home to trillions of bacteria, but they're not meant to be everywhere in equal numbers. The large intestine (colon) is supposed to be the bacterial metropolis. The small intestine, by contrast, is normally relatively sparse: fewer than 10³ colony-forming units per millilitre of fluid in the proximal small bowel.1

SIBO occurs when bacteria, either relocated from the colon or overgrown from normal small intestinal residents, proliferate in the small intestine in numbers that disrupt normal digestive function. Estimates of SIBO prevalence vary widely depending on the diagnostic method used, but studies suggest it affects somewhere between 2.5–22% of the general population, with significantly higher rates in people with irritable bowel syndrome (IBS). A systematic review found SIBO prevalence in IBS patients ranging from roughly 4% to over 50% depending on the diagnostic test used, with culture-based methods yielding the lowest estimates and breath tests the highest.2

Women are disproportionately represented in SIBO diagnoses. This isn't coincidental — hormonal, anatomical, and physiological factors specific to female biology all appear to influence gut motility and bacterial dynamics in meaningful ways.

Why Women Are More Vulnerable

Hormones and Gut Motility

Sex hormones have profound effects on gastrointestinal function. Progesterone, which rises significantly in the luteal phase of the menstrual cycle and during pregnancy, has well-documented inhibitory effects on gut motility because it relaxes smooth muscle throughout the GI tract.3 Slower gut movement means food and bacteria spend longer in the small intestine, creating conditions that favour bacterial overgrowth.

This is why many women notice their digestive symptoms worsen in the week before their period, or during pregnancy — a period when SIBO risk is dramatically elevated. Pregnancy is associated with significantly slowed small bowel transit time, particularly in the third trimester, which creates conditions favourable to bacterial overgrowth.4

Women with PCOS, who have chronically elevated androgen levels and altered sex hormone ratios, also appear to have higher rates of gut dysbiosis and may be at elevated risk of altered gut microbial diversity.5 Women going through perimenopause and menopause — during which oestrogen decline accelerates gut motility changes — also report increased GI symptoms that may partly reflect SIBO.

The Hypothyroid Connection

Hypothyroidism, which is far more common in women (affecting roughly 5–10 times as many women as men), slows the entire body including the gut. Thyroid hormone is essential for maintaining the migrating motor complex (MMC), the fasting "housekeeping" wave of contractions that sweeps bacteria from the small intestine between meals.6 When thyroid function is suboptimal, the MMC weakens, and bacterial overgrowth becomes more likely. A study of hypothyroid patients found a significantly higher prevalence of SIBO compared to euthyroid controls.7

Endometriosis

Endometriosis, affecting roughly 10% of women of reproductive age, causes lesions on and around the bowel in a significant proportion of cases. These lesions can create adhesions, alter bowel motility, and disrupt the normal gut environment, all of which increase SIBO risk. In an uncontrolled case series of women with endometriosis and GI symptoms, 80% (40 of 50) demonstrated bacterial overgrowth on breath testing, and more recent controlled studies confirm a higher prevalence of SIBO in endometriosis compared to healthy women.8

Recognising SIBO: Symptoms in Women

SIBO wears many disguises, which is part of why it goes undiagnosed for years in many women. Here are the key symptoms to know:

Digestive Symptoms

  • Bloating: the hallmark symptom. Often described as immediate or appearing within 30–90 minutes of eating, and frequently severe ("I look pregnant"). Bloating results from bacteria fermenting carbohydrates in the small intestine and producing excess gas.9
  • Abdominal distension: visible expansion of the abdomen, particularly in the afternoon and evening.
  • Abdominal pain or cramping, often relieved by defecation.
  • Altered bowel habits: SIBO can present with diarrhoea, constipation, or alternating between both, depending on the type of gas-producing bacteria involved:
    • Hydrogen-dominant SIBO is more commonly associated with diarrhoea.
    • Methane-dominant SIBO (now called intestinal methanogen overgrowth or IMO) is strongly associated with constipation — methane gas directly slows gut transit.10
    • Hydrogen sulphide SIBO is a newly recognised subtype associated with diarrhoea and a distinctive sulphur odour.
  • Excessive belching or flatulence.
  • Nausea, particularly after eating.
  • Feeling full quickly: early satiety.

Systemic Symptoms

What makes SIBO genuinely systemic — not just a gut problem — is its downstream effects:

  • Fatigue and brain fog: Bacterial overgrowth impairs absorption of key nutrients: Vitamin B12, iron, fat-soluble vitamins, and produces toxins that circulate systemically.11
  • Nutrient deficiencies: Malabsorption of B12 (used by bacteria), fat-soluble vitamins (A, D, E, K) when bile acids are deconjugated, and iron are well-documented consequences.12
  • Joint pain: Some research suggests bacterial products from SIBO may trigger systemic inflammation.
  • Skin issues: Rosacea has been significantly associated with SIBO in multiple studies. A 2008 study found eradication of SIBO led to dramatic improvement or complete remission of rosacea in a majority of patients.13
  • Restless legs syndrome: Iron deficiency secondary to SIBO may be a driver.
  • Anxiety and mood changes: The gut-brain axis is bidirectional, and gut-derived metabolites from SIBO may influence neurotransmitter systems.14
  • Histamine intolerance symptoms: Certain SIBO-causing bacteria are high producers of histamine; symptoms include flushing, hives, headaches, and worsening allergy-like reactions.

What Causes SIBO? The Root Triggers

Understanding causes is essential, because treating SIBO without addressing the underlying driver leads almost inevitably to recurrence. The most important root causes include:

1. Impaired Migrating Motor Complex (MMC)

The MMC is the gut's self-cleaning cycle. A series of contractions that sweep the small intestine every 90–120 minutes during fasting, pushing bacteria downstream to the colon.15 The MMC only activates in a fasted state; this is one reason constant grazing and snacking can predispose to SIBO. Any condition that impairs the MMC like hypothyroidism, chronic stress, diabetes with autonomic neuropathy, use of proton pump inhibitors (PPIs) can increase SIBO risk.6

2. Low Stomach Acid (Hypochlorhydria)

Stomach acid is one of the body's primary defences against bacterial overgrowth. It kills most bacteria before they can colonise the small intestine. Chronic use of PPIs (taken by tens of millions of people for acid reflux) significantly reduces stomach acid and has been associated with a significantly increased risk of SIBO.16 Ageing, autoimmune conditions affecting the stomach lining, and H. pylori infection also reduce acid secretion.

3. Structural Abnormalities and Post-Surgical Changes

Adhesions from prior abdominal surgeries, diverticula in the small bowel, and strictures from conditions like Crohn's disease all create anatomical pockets where bacteria can pool and proliferate. Previous appendectomy and ileocecal valve dysfunction (the valve separating the small and large intestine) are also recognised risk factors.17

4. Prior Acute Infections: Post-Infectious IBS and SIBO

A significant proportion of SIBO cases are triggered by acute gastroenteritis. Food poisoning and gut infections generate an immune response in which antibodies against the bacterial toxin CDT-B cross-react with vinculin — a protein critical for gut motility. This autoimmune process damages the enteric nervous system and impairs the MMC long after the acute infection has resolved.18 This is a major and historically underappreciated cause of chronic SIBO.

5. Stress and the Gut-Brain Axis

Psychological stress profoundly alters gut motility, intestinal permeability, and the composition of the gut microbiome. Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis, releasing cortisol and activating the sympathetic nervous system. Both of which suppress GI motility and alter the mucosal immune environment.19 Women with SIBO often have a history of chronic stress or significant adverse life events.

How SIBO Damages the Liver: The Gut-Liver Axis

This is where the story takes a turn that most people don't fully appreciate. Your small intestine and liver are anatomically and functionally joined at the hip. All blood leaving the gut (carrying nutrients, bacterial products, and whatever else the intestinal lining allows through) travels through the portal vein directly to the liver. The liver is the first line of defence against anything that crosses the gut barrier.

Under normal circumstances, the healthy gut epithelium is a highly selective barrier — it allows nutrients through while keeping bacteria and their toxic byproducts out. SIBO disrupts this in several ways, and the consequences for the liver are significant.

1. Increased Intestinal Permeability ("Leaky Gut")

Bacteria in the small intestine produce enzymes and metabolites that directly damage the tight junctions between intestinal epithelial cells. Studies in both animal models and humans have demonstrated that SIBO is associated with significantly increased intestinal permeability.20 When tight junctions loosen, bacterial products (particularly lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls) translocate across the gut wall and enter the portal circulation.

2. Lipopolysaccharide and Liver Inflammation

LPS is one of the most potent triggers of liver inflammation known. When it arrives at the liver via the portal vein, it binds to Toll-like receptor 4 (TLR-4) on Kupffer cells (the liver's resident immune cells), triggering a cascade of pro-inflammatory cytokine production: TNF-α, IL-1β, IL-6.21 In acute doses, this is a protective immune response. When chronically elevated, as happens in ongoing SIBO, this constitutes persistent, low-grade hepatic inflammation.

This is not a theoretical pathway. A landmark study by Wigg and colleagues found that patients with NASH had a significantly higher prevalence of SIBO compared to healthy controls. Subsequent work has shown that intestinal permeability is increased in NAFLD/NASH and correlates with the severity of hepatic steatosis.22 In a real sense, gut bacteria appear to be fuelling liver inflammation.

3. Bile Acid Dysregulation

Under normal conditions, bile acids released by the liver into the small intestine to assist fat digestion are efficiently reabsorbed in the terminal ileum and recycled back to the liver (enterohepatic circulation). Bacteria in the small intestine prematurely deconjugate bile acids: a process that converts them into forms that are poorly absorbed and cytotoxic to the intestinal lining.23 This disrupts fat-soluble vitamin absorption, impairs the mucosal barrier, and alters the signalling functions of bile acids (which, beyond digestion, act as important metabolic hormones regulating glucose, lipid and energy metabolism via receptors like FXR and TGR5).24

4. Short-Chain Fatty Acid Imbalance and Hepatic Steatosis

While short-chain fatty acids (SCFAs) from colonic fermentation are generally beneficial, excessive production of SCFAs, particularly acetate, in the small intestine from carbohydrate fermentation by SIBO bacteria reaches the liver in large amounts and becomes a substrate for de novo lipogenesis (liver fat production).25 This is one mechanism by which SIBO may contribute directly to hepatic fat accumulation.

5. Ethanol Production by Gut Bacteria

In a remarkable phenomenon known as auto-brewery syndrome or gut fermentation syndrome, certain bacteria in the small intestine, notably Klebsiella pneumoniae, can produce significant quantities of ethanol from carbohydrate fermentation.26 Even at sub-intoxicating levels, chronically elevated endogenous ethanol reaching the liver can promote oxidative stress and hepatocyte damage, mimicking aspects of alcoholic liver injury in people who consume little or no alcohol. A 2019 study published in Cell Metabolism identified high-alcohol-producing strains of Klebsiella pneumoniae in approximately 60% of patients with non-alcoholic fatty liver disease, and demonstrated that gavage of these strains induced fatty liver in mice.27

Diagnosing SIBO: The Current Tools

The most widely used diagnostic test for SIBO is the lactulose or glucose hydrogen/methane breath test. You consume a sugar solution, and breath hydrogen and methane are measured at intervals. Since human cells don't produce these gases, only bacteria do, elevated levels indicate fermentation in the small intestine.28

The test has limitations: sensitivity and specificity vary; lactulose tests in particular have interpretation challenges. The gold standard: direct culture of small intestinal aspirate obtained via endoscopy, is invasive and rarely done in clinical practice. However, a positive breath test in the right clinical context is generally considered adequate for diagnosis and treatment decisions.

Important note for women: Cycle timing may matter. Some practitioners suggest testing in the follicular phase (early cycle) to avoid the confounding effects of progesterone-driven motility changes.

Treatment: Addressing SIBO and Protecting Your Liver

Antimicrobial Treatment

Rifaximin: a non-absorbable antibiotic that stays in the gut. This is the best-studied pharmaceutical treatment for hydrogen-dominant SIBO. Multiple RCTs have demonstrated its efficacy in both normalising breath tests and improving IBS-like symptoms.29 For methane-dominant SIBO/IMO, rifaximin is typically combined with neomycin for better efficacy.30

Herbal antimicrobial protocols using combinations such as berberine, allicin, oregano oil, and neem have shown promising efficacy in small studies, with one 2014 study finding herbal therapy was as effective as rifaximin for hydrogen SIBO.31 These may be particularly useful for patients who prefer to avoid antibiotics or have had recurrences.

Note: Antibiotics alone frequently lead to recurrence if the underlying cause isn't addressed. Recurrence rates within 9 months can be 40–50%.32

Addressing Root Causes (Non-Negotiable for Lasting Results)

  • Support the MMC: Space meals 4–5 hours apart to allow MMC activation. Ginger has demonstrated prokinetic effects on gastric and small intestinal motility, and low-dose naltrexone has been used clinically to modulate motility in IBS, although evidence specific to SIBO recurrence is limited.33
  • Optimise thyroid function if hypothyroidism is present.
  • Review and minimise PPI use in consultation with your doctor if long-term use is a contributing factor.
  • Treat underlying SIBO triggers: adhesions, structural issues, motility disorders.
  • Stress management: given the HPA-gut axis relationship, this is genuine medicine.

Dietary Support During and After Treatment

  • The Low-FODMAP diet reduces fermentable carbohydrates that feed SIBO bacteria and can significantly reduce symptoms during treatment, though it is not a cure.34
  • Elemental diet: a pre-digested liquid formula that "starves" bacteria and has shown high success rates in normalising breath tests; used particularly in refractory or severe cases.35
  • After treatment, gradually reintroduce diverse fibre to support a healthy colonic microbiome. The goal is a thriving, diverse colon, not permanent bacterial restriction.

Protecting and Supporting the Liver

Given the liver involvement, specific strategies are warranted:

  • Milk thistle (silymarin): Has demonstrated hepatoprotective effects, reducing hepatic inflammation and supporting regeneration.36
  • Reduce gut bacterial load: Treating SIBO effectively and durably is the most direct way to reduce LPS load reaching the liver.
  • Avoid alcohol and unnecessary hepatotoxic medications during periods of suspected liver stress.
  • Support bile flow: Bile salts, choline, and bitter herbs (artichoke, dandelion) can support bile production and flow, aiding fat digestion and the enterohepatic circulation.

When to Seek Further Investigation

See a doctor promptly if you have:

  • Unintentional weight loss
  • Blood in stools
  • Persistent vomiting
  • Symptoms after age 50 that are new
  • Elevated liver enzymes on blood work alongside gut symptoms
  • Signs of malnutrition or significant nutrient deficiency

These warrant investigation to rule out more serious pathology before SIBO is assumed.

The Bottom Line

SIBO is not just a bloating problem. It is a systemic condition with documented pathways to nutritional deficiency, hormonal disruption, skin disease, neurological symptoms and, critically, liver damage. Women face a unique convergence of risk factors like hormonal cycles, thyroid vulnerability, endometriosis, post-infectious susceptibility, that make them disproportionately affected.

Understanding that the gut and liver are in constant conversation, with everything crossing the small intestinal barrier making a direct journey to the liver, reframes what it means to take gut health seriously. It's not wellness jargon. It's anatomy.

References

  1. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443–1454. PMID: 17990113
  2. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–1286. PMID: 19602448
  3. Wald A, Van Thiel DH, Hoechstetter L, et al. Effect of pregnancy on gastrointestinal transit. Dig Dis Sci. 1982;27(11):1015–1018. PMID: 7140485
  4. Lawson M, Kern F, Everson GT. Gastrointestinal transit time in human pregnancy: prolongation in the second and third trimesters followed by postpartum normalization. Gastroenterology. 1985;89(5):996–999. PMID: 4043680
  5. Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103(4):1502–1511. PMID: 29340590
  6. Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47(12):2639–2643. PMID: 12498278
  7. Srivastava S, Bhatt SP, Mishra MN. Assessment of small intestinal bacterial overgrowth in subclinical and overt hypothyroidism. Indian J Gastroenterol. 2021;40(3):313–319. PMID: 34406634
  8. Mathias JR, Franklin R, Quast DC, et al. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998;70(1):81–88. PMID: 9660426
  9. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503–3506. PMID: 11151884
  10. Pimentel M, Mayer AG, Park S, et al. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48(1):86–92. PMID: 12645795
  11. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978–2990. PMID: 20572300
  12. Teo M, Chung S, Chitti L, et al. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastroenterol Hepatol. 2004;19(8):904–909. PMID: 15242494
  13. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759–764. PMID: 18456568
  14. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926–938. PMID: 25689247
  15. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158–1166. PMID: 560611
  16. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–490. PMID: 23270866
  17. Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth—prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674–688. PMID: 23957651
  18. Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015;10(5):e0126438. PMID: 25970536
  19. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591–599. PMID: 22314561
  20. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877–1887. PMID: 19358219
  21. Szabo G, Petrasek J. Gut-liver axis and sterile signals in the development of alcoholic liver disease. Alcohol Alcohol. 2017;52(4):414–424. PMID: 28482048
  22. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48(2):206–211. PMID: 11156641
  23. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241–259. PMID: 16299351
  24. Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32(Suppl 2):S237–245. PMID: 19875558
  25. Zhao S, Jang C, Liu J, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature. 2020;579(7800):586–591. PMID: 32214246
  26. Painter K, Cordell BJ, Sticco KL. Auto-Brewery Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 29630222
  27. Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30(4):675–688. PMID: 31543403
  28. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775–784. PMID: 28323273
  29. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. PMID: 21208106
  30. Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547–550. PMID: 20400905
  31. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16–24. PMID: 24891990
  32. Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103(8):2031–2035. PMID: 18802998
  33. Pimentel M, Morales W, Lezcano S, et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. J Clin Gastroenterol. 2009;43(4):e80–e86. PMID: 18813024
  34. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75. PMID: 24076059
  35. Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49(1):73–77. PMID: 14992438
  36. Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279–1301. PMID: 32006251
Back to Articles
Change country
logo-paypal paypal